Partners
The ERA4TB Consortium brings together a multi-disciplinary team with proven expertise and capabilities in TB drug development to profile and progress anti-TB compounds up to completion of Phase I.
The project consortium integrates 31 organizations, namely eight prestigious academic institutions (UC3M, UNIZAR, UU, EPFL, UKÖ, UNIPD, UPV, LUND), four non-profit organizations (IPP, IPL, iM4TB, BAR), eight public research organizations (FZB, CNR, IDMIT, SERMAS, PHE, NICE, SCI, IOS) and five highly skilled small-medium enterprises (SYNAPSE, C-Path, IBT, QPS, GRIT42), together with three EFPIA members (GSK, EVT, JANSSEN), and three IMI2 Associated Partners (BMGF, TBA, DDU).